中文

美康生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.38B+0.5%
Gross profit¥0.14B
Operating income¥0.04B
Net income¥0.03B+11.4%
Gross margin38.5%Net margin 8.8%
Revenue Q/Q-6.8%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.23B61.5%
R&D¥0.03B7.7%
SG&A¥0.09B23.0%
Tax & other¥0.00B1.2%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

运达科技鲍斯股份金雷股份双杰电气康斯特航天智造全信股份浩云科技汉邦高科创业慧康山河药辅三鑫医疗

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies